ATE467642T1 - Derivatisierung des granulozytenkoloniestimulierenden faktors - Google Patents

Derivatisierung des granulozytenkoloniestimulierenden faktors

Info

Publication number
ATE467642T1
ATE467642T1 AT07789047T AT07789047T ATE467642T1 AT E467642 T1 ATE467642 T1 AT E467642T1 AT 07789047 T AT07789047 T AT 07789047T AT 07789047 T AT07789047 T AT 07789047T AT E467642 T1 ATE467642 T1 AT E467642T1
Authority
AT
Austria
Prior art keywords
coloney
derivatization
granulocyte
stimulating factor
protein
Prior art date
Application number
AT07789047T
Other languages
English (en)
Inventor
Sanjay Jain
Peter Laing
Gregory Gregoriadis
Original Assignee
Lipoxen Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipoxen Technologies Ltd filed Critical Lipoxen Technologies Ltd
Application granted granted Critical
Publication of ATE467642T1 publication Critical patent/ATE467642T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
AT07789047T 2006-07-25 2007-07-25 Derivatisierung des granulozytenkoloniestimulierenden faktors ATE467642T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06117830 2006-07-25
PCT/GB2007/002816 WO2008012525A1 (en) 2006-07-25 2007-07-25 Derivatisation of granulocyte colony-stimulating factor

Publications (1)

Publication Number Publication Date
ATE467642T1 true ATE467642T1 (de) 2010-05-15

Family

ID=37397314

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07789047T ATE467642T1 (de) 2006-07-25 2007-07-25 Derivatisierung des granulozytenkoloniestimulierenden faktors

Country Status (10)

Country Link
US (22) US8299026B2 (de)
EP (6) EP2043616B1 (de)
JP (14) JP5096466B2 (de)
KR (1) KR101400105B1 (de)
CN (2) CN103169984B (de)
AT (1) ATE467642T1 (de)
DE (1) DE602007006492D1 (de)
ES (5) ES2647528T3 (de)
RU (1) RU2432175C2 (de)
WO (4) WO2008012525A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807824B2 (en) * 2003-08-12 2010-10-05 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
EP1654289B1 (de) 2003-08-12 2007-10-03 Lipoxen Technologies Limited Polysialinsäurederivate
EP2043616B1 (de) 2006-07-25 2016-01-27 Lipoxen Technologies Limited Kupplung von polysialinsäure am n-terminus von proteinen
CN101557830B (zh) 2006-12-15 2016-06-08 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
EP2115010B1 (de) 2007-02-28 2011-10-19 Lipoxen Technologies Limited Verringerung von endotoxin in polysialinsäuren
BRPI0815324A2 (pt) * 2007-08-20 2015-07-14 Protalix Ltd "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos"
RU2391354C1 (ru) * 2008-10-15 2010-06-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН, Российская Федерация, от имени которой выступает Федеральное агентство по науке и инновациям Комплекс биологически активного рекомбинантного белка с полисиаловой кислотой
EP2337794B1 (de) * 2008-10-20 2013-07-31 USV Limited Verbessertes verfahren zur proteinpegylierung
CA2742064A1 (en) * 2008-10-31 2010-05-06 Amgen Inc. Materials and methods relating to stem cell mobilization by multi-pegylated granulocyte colony stimulating factor
BRPI1007466A2 (pt) 2009-01-28 2018-06-12 Smartcells Inc conjugado de insulina cristalina, formulação de liberação prolongada, e, sistema de distribuição de bomba
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
CA2750223A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
JP5508438B2 (ja) 2009-01-28 2014-05-28 スマートセルズ・インコーポレイテツド 制御された薬物送達のための複合体に基づくシステム
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
AU2010226243A1 (en) 2009-03-20 2011-09-22 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
CA2769244A1 (en) * 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
CN104530182A (zh) * 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2595442C2 (ru) 2009-07-27 2016-08-27 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
CN101787117B (zh) * 2010-02-08 2012-05-23 江南大学 聚乙二醇-聚唾液酸嵌段共聚物的制备方法及应用
US8927488B2 (en) * 2010-05-17 2015-01-06 Cebix, Inc. Pegylated C-peptide
WO2011156242A2 (en) * 2010-06-11 2011-12-15 Lpath, Inc. Improved anti-lysophospholipid antibody design using antibody structures
CA2806399A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
CA2805739A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
US9068013B2 (en) 2010-07-28 2015-06-30 Smart Cells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
DK2665814T3 (en) 2011-01-20 2017-09-11 Protalix Ltd NUCLEIC ACID CONSTRUCTION FOR EXPRESSION OF ALPHA-GALACTOSIDASE IN PLANTS AND PLANT CELLS
CN104220086A (zh) 2011-11-17 2014-12-17 塞比克斯股份公司 Peg化的c-肽
MX366852B (es) 2013-10-04 2019-07-25 Merck Sharp & Dohme Conjugados de insulina sensibles a glucosa.
US10188739B2 (en) 2014-02-27 2019-01-29 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
JP2019218265A (ja) * 2016-09-14 2019-12-26 生化学工業株式会社 ペプチドの血中滞留性を増強させる方法
WO2018197547A1 (en) 2017-04-25 2018-11-01 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
WO2018197545A1 (en) * 2017-04-25 2018-11-01 Lipoxen Technologies Limited Methods of treating multiple myeloma cancers expressing high levels of epo-receptor using psa-epo
WO2020099513A1 (en) * 2018-11-13 2020-05-22 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
JP2022519586A (ja) * 2019-02-04 2022-03-24 ゼネティック バイオサイエンシーズ インコーポレイテッド 糖ポリシアル酸化治療用タンパク質を使用する方法
CA3145382A1 (en) 2019-07-08 2021-01-14 Gi Innovation, Inc. Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of ige fc receptor, and pharmaceutical composition comprising same
CN116249552A (zh) * 2020-08-11 2023-06-09 隆延生物科技（上海）有限公司 一种液体制剂及其应用
CN114966021B (zh) * 2022-05-19 2025-03-04 山东博科生物产业有限公司 一种稳定的脂蛋白相关磷脂酶a2测定试剂盒

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2930542A1 (de) 1979-07-27 1981-02-12 Hoechst Ag Neue insulinderivate und verfahren zu ihrer herstellung
US5308617A (en) * 1988-08-10 1994-05-03 Halzyme Ltd. Protein heparin conjugates
KR100221066B1 (ko) 1989-10-13 1999-10-01 스튜어트 엘.왓트 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물
US7217689B1 (en) * 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
GB9112212D0 (en) 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
DK0550108T3 (da) 1991-12-30 1999-01-04 Akzo Nobel Nv Thyreoaktiv sammensætning med langvarig frigivelse
JP2747967B2 (ja) * 1993-07-23 1998-05-06 雪印乳業株式会社 シアル酸粉末
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
ES2187047T3 (es) * 1997-08-05 2003-05-16 Bioniche Life Sciences Inc Composicion y metodo para la regulacion de la proliferacion celular y la muerte celular.
WO1999043307A1 (en) 1998-02-26 1999-09-02 Prange Arthur J Jr Thyroid hormone replacement using sustained release triiodothyronine
RU2141531C1 (ru) 1999-05-26 1999-11-20 Российское акционерное общество открытого типа "Биопрепарат" Способ получения рекомбинантного инсулина человека
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
ES2256234T3 (es) 2000-05-16 2006-07-16 Lipoxen Technologies Limited Derivatizacion de proteinas en solucion acuosa.
CA2408956C (en) 2000-05-18 2011-07-12 Therics, Inc. Method and form of a drug delivery device,such as encapsulating a toxic core within a non-toxic region in an oral dosage form
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
EP1333036B1 (de) * 2000-10-16 2009-01-21 Chugai Seiyaku Kabushiki Kaisha Peg-modifiziertes erythropoietin
JP4656814B2 (ja) 2000-12-20 2011-03-23 エフ．ホフマン−ラ ロシュ アーゲー エリスロポエチンコンジュゲート
KR100401296B1 (ko) 2000-12-27 2003-10-11 드림바이오젠 주식회사 수식물질에 의해 수식된 단백질 변이체 및 이것의 제조방법
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
CA2462930C (en) 2001-10-10 2012-07-10 Shawn De Frees Remodeling and glycoconjugation of peptides
WO2003055526A2 (en) 2001-12-21 2003-07-10 Maxygen Aps Erythropoietin conjugates
ITPD20010302A1 (it) 2001-12-28 2003-06-28 Bbs Riva Spa Dispositivo idraulico per pompare e / p intercettare metallo allo stato fuso
US6763226B1 (en) 2002-07-31 2004-07-13 Computer Science Central, Inc. Multifunctional world wide walkie talkie, a tri-frequency cellular-satellite wireless instant messenger computer and network for establishing global wireless volp quality of service (qos) communications, unified messaging, and video conferencing via the internet
MXPA05002594A (es) * 2002-09-11 2005-05-27 Fresenius Kabi Gmbh Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
EP1400533A1 (de) * 2002-09-11 2004-03-24 Fresenius Kabi Deutschland GmbH Hasylierte Polypeptide, besonders hasyliertes Erythropoietin
EP1681303B1 (de) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylierte Polypeptide, besonders HASyliertes Erythropoietin
CN1777440A (zh) * 2003-04-11 2006-05-24 Pr药品有限公司 位点特异性蛋白质偶联物的制备方法
WO2004101619A1 (ja) * 2003-05-15 2004-11-25 Shionogi Co., Ltd. 機能的糖ペプチドの合理的設計および合成
US7074755B2 (en) * 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
DE602004016170D1 (de) 2003-07-03 2008-10-09 Cipla Ltd Verfahren zur herstellung von finasterid form i
ATE345995T1 (de) 2003-08-05 2006-12-15 Dematic Corp Querantrieb für motorisierte rolle
CN102151331B (zh) * 2003-08-06 2013-10-30 美国政府健康及人类服务部 多糖-蛋白轭合物疫苗
AU2004262921B2 (en) * 2003-08-08 2010-05-13 Octapharma Ag Conjugates of hydroxyalkyl starch and G-CSF
US7807824B2 (en) 2003-08-12 2010-10-05 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
EP1654289B1 (de) 2003-08-12 2007-10-03 Lipoxen Technologies Limited Polysialinsäurederivate
ES2445948T3 (es) * 2003-11-24 2014-03-06 Ratiopharm Gmbh Eritropoyetina glicopegilada
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
AU2004296855B2 (en) * 2003-12-03 2011-01-06 Ratiopharm Gmbh Glycopegylated Granulocyte Colony Stimulating Factor
CN101659704A (zh) * 2004-03-11 2010-03-03 弗雷泽纽斯卡比德国有限公司 通过还原氨基化制备的羟烷基淀粉和蛋白质的偶联物
FR2868071B1 (fr) * 2004-03-26 2006-06-09 Biomerieux Sa Reactifs de marquage, procedes de synthese de tels reactifs et procedes de detection de molecules biologiques
DE102004030392A1 (de) 2004-06-23 2006-01-19 Endress + Hauser Flowtec Ag, Reinach Meßwandler vom Vibrationstyp
WO2006014148A2 (fr) 2004-08-04 2006-02-09 Sergey Alexandrovich Orlov Procede permettant d'organiser un processus de jeu a action intermittente
GB2416993A (en) 2004-08-11 2006-02-15 Dinesh Verma Opthalmic prosthesis
US8652334B2 (en) 2004-08-12 2014-02-18 Lipoxen Technologies Limited Fractionation of charged polysaccharide
EP1776389B1 (de) * 2004-08-12 2016-06-29 Lipoxen Technologies Limited Sialinsäurederivate
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖ｐｅｇ化顆粒球コロニー刺激因子
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
CN103626884B (zh) 2005-02-23 2016-05-18 利普生技术有限公司 用于蛋白质衍生和缀合的活化的唾液酸衍生物
JP3989936B2 (ja) * 2005-04-07 2007-10-10 進 須永 抗腫瘍剤及び新規ｄｎアーゼ
WO2007047997A2 (en) 2005-10-19 2007-04-26 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
EP2043616B1 (de) 2006-07-25 2016-01-27 Lipoxen Technologies Limited Kupplung von polysialinsäure am n-terminus von proteinen
US8933025B2 (en) 2009-07-16 2015-01-13 Kao Corporation Agent for suppressing postprandial elevation of blood insulin concentration
JO3476B1 (ar) 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية

Also Published As

Publication number Publication date
CN101511391B (zh) 2013-03-13
ES2581983T3 (es) 2016-09-08
JP2016128493A (ja) 2016-07-14
US8299026B2 (en) 2012-10-30
JP6165079B2 (ja) 2017-07-19
EP2041167A1 (de) 2009-04-01
US20100056427A1 (en) 2010-03-04
JP6243456B2 (ja) 2017-12-06
US20180289823A1 (en) 2018-10-11
JP5542195B2 (ja) 2014-07-09
EP2043692B1 (de) 2016-05-18
US9492556B2 (en) 2016-11-15
KR20090057370A (ko) 2009-06-05
US20170119893A1 (en) 2017-05-04
JP5419689B2 (ja) 2014-02-19
US20140315802A1 (en) 2014-10-23
WO2008012540A1 (en) 2008-01-31
JP5912152B2 (ja) 2016-04-27
WO2008012542A8 (en) 2009-07-16
US9492557B2 (en) 2016-11-15
WO2008012528A1 (en) 2008-01-31
JP6055506B2 (ja) 2016-12-27
US8946406B2 (en) 2015-02-03
JP2009544681A (ja) 2009-12-17
JP5941440B2 (ja) 2016-06-29
US8796207B2 (en) 2014-08-05
US20150252090A1 (en) 2015-09-10
JP2013241446A (ja) 2013-12-05
US20170058273A1 (en) 2017-03-02
US9789163B2 (en) 2017-10-17
US20100022443A1 (en) 2010-01-28
KR101400105B1 (ko) 2014-06-19
US20100016217A1 (en) 2010-01-21
US9266936B2 (en) 2016-02-23
ES2647528T3 (es) 2017-12-22
EP2630972A3 (de) 2013-10-16
RU2432175C2 (ru) 2011-10-27
US20140309407A1 (en) 2014-10-16
US20160095930A1 (en) 2016-04-07
WO2008012542A3 (en) 2008-05-15
WO2008012542A2 (en) 2008-01-31
US10300144B2 (en) 2019-05-28
US20130116176A1 (en) 2013-05-09
JP2013100309A (ja) 2013-05-23
JP2013121982A (ja) 2013-06-20
JP2015007062A (ja) 2015-01-15
CN103169984A (zh) 2013-06-26
EP2043616A1 (de) 2009-04-08
US20160129124A1 (en) 2016-05-12
WO2008012525A8 (en) 2010-04-29
US20190216938A1 (en) 2019-07-18
US8394921B2 (en) 2013-03-12
US9579393B2 (en) 2017-02-28
JP5586669B2 (ja) 2014-09-10
JP6203342B2 (ja) 2017-09-27
EP3299033A1 (de) 2018-03-28
RU2009105696A (ru) 2010-08-27
JP6581157B2 (ja) 2019-09-25
JP2018039791A (ja) 2018-03-15
JP2013049675A (ja) 2013-03-14
US20140134147A1 (en) 2014-05-15
EP2630972A2 (de) 2013-08-28
JP2015145400A (ja) 2015-08-13
ES2569066T3 (es) 2016-05-06
JP2009544677A (ja) 2009-12-17
US9040478B2 (en) 2015-05-26
ES2581902T3 (es) 2016-09-08
US20170080054A1 (en) 2017-03-23
CN103169984B (zh) 2016-08-03
ES2344670T3 (es) 2010-09-02
WO2008012540A9 (en) 2009-03-12
US20150158924A1 (en) 2015-06-11
JP5420091B2 (ja) 2014-02-19
EP2043616B1 (de) 2016-01-27
EP2043692A2 (de) 2009-04-08
JP5096466B2 (ja) 2012-12-12
DE602007006492D1 (de) 2010-06-24
US8933026B2 (en) 2015-01-13
US8981050B2 (en) 2015-03-17
CN101511391A (zh) 2009-08-19
JP2014114315A (ja) 2014-06-26
US20220133898A1 (en) 2022-05-05
EP2043693A1 (de) 2009-04-08
US20150147307A1 (en) 2015-05-28
EP2043693B1 (de) 2016-04-27
WO2008012525A1 (en) 2008-01-31
US9474805B2 (en) 2016-10-25
US20160129123A1 (en) 2016-05-12
JP2009544678A (ja) 2009-12-17
US20100022441A1 (en) 2010-01-28
EP2041167B1 (de) 2010-05-12
US20140309166A1 (en) 2014-10-16
JP2017018107A (ja) 2017-01-26
US20140161765A1 (en) 2014-06-12
US9549990B2 (en) 2017-01-24
JP2009544680A (ja) 2009-12-17
EP2630972B1 (de) 2017-08-30
US8299015B2 (en) 2012-10-30
US9234020B2 (en) 2016-01-12

Similar Documents

Publication Publication Date Title
ATE467642T1 (de) Derivatisierung des granulozytenkoloniestimulierenden faktors
EP2360170A3 (de) Selektive Reduktion und Derivatisierung von Proteinen die mindestens ein nicht-natives Cystein enthalten
NO20083948L (no) Glykosylerte antistoffer
UA94221C2 (en) Lipocalin protein
BRPI0519046A2 (pt) composição de xampu
IL186741A0 (en) Optical probe for delivery of light
CL2011000207A1 (es) Composicion biocida que comprende ciprodinil y flutianil; metodo para controlar enfermedades en plantas utiles o en material de propagacion causadas por fitopatogenos (div. sol. n°2602-06).
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
WO2006133088A3 (en) Improved human interferon molecules and their uses
WO2007065082A3 (en) Digital hydraulic system
IL188611A (en) Type 1sp polypeptides are altered at the n-terminal end and used
MX2008004734A (es) Composicion rica en leucina.
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
MX341064B (es) Variantes de la familia il-1.
TW200724159A (en) Stable emulsion composition
DE602007014249D1 (en) Lung
PL1922128T3 (pl) Element do zmniejszania zawartości drobnego pyłu w powietrzu, za pomocą mchów i/lub porostów
WO2006106348A3 (en) Protein glycosylation
PL1848918T5 (pl) Urządzenie oświetleniowe
ATE452646T1 (de) Zusammensetzungen mit epigallocatechingallat und proteinhydrolysat
PL1723263T3 (pl) Spiekane tworzywo na łożysko ślizgowe, kompozyt na łożysko ślizgowe oraz jego zastosowania
DE602004007890D1 (de) Schweinekollagenfilm
ATE320474T1 (de) Transparentes wässriges beschichtungsmittel mit glasmehl
MX2007007355A (es) 5-(2,2-dimetil-ciclopropil)-3-metil-pen-2-en nitrilo como fragancia y sabor.
DE50310896D1 (de) Regneranordnung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties